Concepedia

Author

Zafer E. Ozturk

Regeneron (United States)

Also Known As

Z E Ozturk, Z. E. Ozturk, Zafer E Ozturk, Zafer E Öztürk, Zafer E. Ozturk, Zafer Ozturk

19

Publications

557

Citations

11

H-Index

4

Concepts

All Affiliations

Regeneron (United States)Sanofi (United States)University Medical Center UtrechtMerck & Co., Inc., Rahway, NJ, USA (United States)Université Claude Bernard Lyon 1
ZE

About

Zafer E. Ozturk is an author at Regeneron (United States) specializing in osteoporosis, medicine, and oral medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

38

2

Anesthesiology

1

1

38

3

Oral Medicine

1

1

38

4

Osteoporosis

1

1

38

Zafer E. Ozturk

×

10

Publications

503

Citations

10

H-Index

YearCitations

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial

Bernard R. Rubin, Robert Burton, Sandra Navarra,

Arthritis & Rheumatism

2004

183

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis

J. Zacher, Daniel Feldman, Roberto Gerli,

Current Medical Research and Opinion

2003

64

Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4‐week, multinational, randomized, double-blind study

Cristiano A. F. Zerbini, Zafer E. Ozturk, Joachim Grifka,

Current Medical Research and Opinion

2005

62

Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry.

Daniel E. Furst, Hong Chang, Jeffrey D. Greenberg,

PubMed

2009

46

Adherence to and Gastrointestinal Tolerability of Monthly Oral or Quarterly Intravenous Ibandronate Therapy in Women with Previous Intolerance to Oral Bisphosphonates: A 12-Month, Open-Label, Prospective Evaluation

E. Michael Lewiecki, Ann M. Babbitt, Veronica Piziak,

Clinical Therapeutics

2008

38

Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis

Jacqueline B. Palmer, Yunfeng Li, Vivian Herrera,

BMC Musculoskeletal Disorders

2016

31

Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study

Marjolein de Bruin‐Weller, Andrew Pink, Annalisa Patrizi,

Journal of Dermatological Treatment

2021

27

Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study

Joseph F. Merola, Albert S. Chiou, Emmanuel During,

British Journal of Dermatology

2023

21

Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study

Lisa A. Beck, Diamant Thaçi, Mette Deleuran,

Journal of Dermatological Treatment

2021

20

Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology

Amy S. Paller, Emma Guttman‐Yassky, Alan D. Irvine,

BMJ Open

2020

11

Page 1